# Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

> **NCT02660736** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 59 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Albiglutide Liquid Auto-injector
- **DRUG:** Albiglutide Lyophilized DCC Pen Injector
- **DRUG:** Placebo Liquid Auto-injector
- **DRUG:** Placebo Lyophilized DCC Pen injector

## Key facts

- **NCT ID:** NCT02660736
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2016-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02660736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02660736, "Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02660736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*